ResultsIQ › Latest results › Molbio Diagnostics Limited
Molbio Diagnostics Limited Q2 FY27 earnings call summary
NSE: MOLBIO · BSE: 544866
Earnings call of 5 Nov 2026, summarised by AI from the filing.
Molbio's H1 FY27 revenue was ₹667 cr versus ₹680 cr, with FY27 guidance of 25% growth and 24-25% EBITDA margin reiterated.
Key takeaways
- FY27 guidance 25% top-line growth and 24-25% EBITDA margin for FY27 reiterated; management says on track.
- Rate contract Renewal pushed about a month, shifting roughly ₹100 cr of revenue from H1 to H2.
- New platforms Trueamp, Truecyte and Truepoc developed in-house; CDSCO licence expected in about 4-5 months.
- PAT pressure PAT softer than H1 FY26 on OptraSCAN term-loan interest and intangible amortisation.
Molbio Diagnostics Limited H1 FY27 results
As filed: Revenue ₹648 cr, EBITDA ₹150 cr, PAT ₹88.0 cr, EBITDA margin 23.2%.
Not scored. No result for the same half-year last year.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹399 cr, EBITDA ₹91.6 cr, PAT ₹56.6 cr, EBITDA margin 22.9%. Not scored. No result for the same quarter last year. Share price after the results: +29.5% in 30 days (Nifty 500: −5.5%).
Past price moves after results do not indicate future moves. Not a recommendation.
Molbio Diagnostics Limited earnings call, investor presentation and press release summaries
Figures from the company's filings with NSE and BSE. Not investment advice.